 |
|
Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease
The ADMIT Study: A Randomized Trial
Marshall B. Elam, PhD, MD;
Donald B. Hunninghake, MD;
Kathryn B. Davis, PhD;
Rekha Garg, MD, MS;
Craig Johnson, MS;
Debra Egan, MSc, MPH;
John B. Kostis, MD;
David S. Sheps, MD;
Eliot A. Brinton, MD;
for the ADMIT Investigators
JAMA. 2000;284:1263-1270.
ABSTRACT
| |
Context Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data.
Objective To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes.
Design and Setting Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995.
Participants A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease.
Interventions After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind).
Main Outcome Measures Plasma lipoprotein, glucose, hemoglobin A1c (HbA1c), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo.
Results Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P = .04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA1c were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA1c decreased by 0.3% (P = .04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo.
Conclusions Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels.
INTRODUCTION
The Arterial Disease Muliple Intervention Trial (ADMIT) was a prospective, placebo-controlled study. ADMIT evaluated the safety and efficacy of a combination of high-density lipoprotein (HDL)–raising, antioxidant vitamin, and low-dose warfarin therapy to modify multiple atherosclerotic vascular disease risk factors in subjects with peripheral arterial disease. Niacin was selected as the intervention in ADMIT to increase HDL levels because it is effective in increasing HDL cholesterol (HDL-C) (and lowering triglycerides),1-4 and has previously been shown to reduce cardiovascular morbidity and mortality.5-8 It was anticipated that a substantial number of ADMIT participants would have diabetes mellitus.9 Despite published guidelines discouraging the use of niacin in the treatment of diabetes10-13; the long-term use of lipid-modifying dosages of niacin in subjects with controlled, stable diabetes has not been examined in a prospective, placebo-controlled, double-blind study. We decided to include participants with diabetes in ADMIT to provide useful information regarding the safety and efficacy of niacin use in that patient population. Of 468 ADMIT participants, 125 patients with diabetes were included. This article describes the effect of niacin treatment on plasma lipoproteins and glycemic status in ADMIT participants with diabetes.
METHODS
Study Design and Organization
The design and rationale of ADMIT have been reported previously.14 ADMIT was a National Heart, Lung, and Blood Institute–sponsored multicenter, randomized, placebo-controlled trial designed to evaluate the feasibility of recruitment of subjects with peripheral arterial disease, and their adherence and response to 3 interventions. These interventions included niacin, antioxidant vitamins, and low-dose warfarin, or corresponding placebo treatments, administered in a 2 x2x2 factorial design.
Participants were enrolled at 6 clinical centers and the data were collected and analyzed by the data coordinating center (Axio Research Corp, Seattle, Wash). An independent data and safety monitoring board kept track of the progress of the trial. The protocol and consent form were approved by the institutional review board at each clinical center. Written informed consent was obtained from all participants prior to enrollment into the study.
Eligibility Criteria
This article presents information on 125 ADMIT enrollees who met study criteria for diabetes at the first study visit. Diabetes was defined as either a history of diabetes treated by diet or medication or a hemoglobin A1c (HbA1c) level higher than 7% at the baseline visit. Inclusion and exclusion criteria for ADMIT have been previously presented.14 ADMIT participants had either a reduced ankle brachial index of less than 0.85 or a history of prior lower-extremity revascularization. Subjects were excluded from ADMIT for poorly controlled diabetes (HbA1c >9.0%), a history of diabetic ketoacidosis or coma, renal disease, liver disease, gout, hyperuricemia, peptic ulcer disease, history of myositis, or untreated hypothyroidism. Participants with marked hypertriglyceridemia (>400 mg/dL) for whom randomization to niacin placebo would not have been appropriate, or whose low-density lipoprotein (LDL) level was not likely to be controlled by niacin and/or pravastatin (baseline LDL cholesterol [LDL-C] >190 mg/dL [4.9 mmol/L]) were also excluded from participation.
Run-in and Randomization
All participants underwent an active niacin run-in, during which crystalline (immediate release) niacin tablets (Niacor, Upsher-Smith, Minneapolis, Minn) were dispensed at 4-week intervals in increasing doses of 50, 250, and 500 mg twice daily.
Participants who successfully completed the active niacin run-in were then randomly assigned to receive a combination of active niacin, antioxidant vitamin cocktail, and warfarin or their respective placebo treatments. Randomization into each of the 8 possible drug combinations (of the 2x2x2 factorial design) was performed independently at each clinical center using block sizes of 8, 16, or 24 selected at random. At randomization, the dosage of niacin or its placebo was increased to 750 mg twice daily with subsequent increases to 1000 mg and then 1500 mg twice daily at 6-week intervals, or until maximum tolerated dose was reached. Participants were to receive 3000 mg/d or the maximum tolerated dosage for the remainder of the 48-week double-blind treatment period.
Fasting blood glucose levels were monitored at 6-week intervals throughout the follow-up period. If the fasting blood glucose level was higher than 189 mg/dL (10.5 mmol/L), the HbA1c level was then measured, and if this was higher than 10.0%, the dosage of niacin (or its placebo) was down-titrated. Niacin down-titration was also performed if any routine HbA1c level (measured at study weeks 6, 24, and 48) was higher than 10.0%. The dosage of niacin (or its placebo) was also down-titrated in any participant whose uric acid level was higher than 595 µmol/L.
Among niacin placebo tablets, 15% contained 50 mg of active niacin. This low dose of niacin was given to cause intermittent flushing in the participants taking niacin placebo to minimize the risk of inadvertent subject unblinding. The average daily dose of niacin in the placebo group was approximately 43 mg/d at maximum, a dosage not known to have a significant effect either on lipids or on the other study parameters. Participants whose LDL-C levels remained above 130 mg/dL (3.4 mmol/L) while taking the maximum dose of niacin or placebo were provided with open-label pravastatin of 10 to 20 mg/d as needed to achieve LDL-C levels of less than 115 mg/dL (3 mmol/L). Thus, pravastatin was given in a nonrandom manner to participants in both the niacin and niacin-placebo groups. To focus on the effects of niacin monotherapy, we only report lipid results from the period prior to pravastatin therapy (first 30 weeks of the study). In contrast, the other end points are reported herein for the full 60 weeks of the study to include all available safety data.
Laboratory Methods
Lipoprotein profiles (total cholesterol, HDL-C, and total triglycerides) were measured on plasma samples, obtained after an overnight fast, using the Centers for Disease Control and Prevention's standardized methods and calibrator standards at the Lipid Analytic Laboratory, Wake Forest University School of Medicine, Winston-Salem, NC. LDL-C was calculated as described by Friedewald et al.15 HbA1c level was measured by high-pressure liquid chromatography (Laboratory Corporation of America, Burlington, NC). Plasma or serum levels of glucose, uric acid, aspartate aminotransferase, and alanine aminotransferase were measured by standard autoanalyzer methods in the local clinical laboratories.
Statistical Analyses
The effect of concurrent treatment with either warfarin or antioxidant vitamins on the lipoprotein and glycemic response to niacin was examined by longitudinal regression analysis. There was no interaction between the effect of niacin and the other treatments on lipoproteins or glycemic control. This report therefore presents data analyzed by niacin treatment assignment only for participants both with and without diabetes. The overall study results, including results of warfarin and antioxidant treatment on the variables of interest for those interventions, will be reported elsewhere.
Descriptive statistics are reported as mean (SD) for continuous variables. Univariate comparisons were made by 2-sided t tests,  2 tests, and Fisher exact tests as appropriate. The follow-up effects of niacin treatment on plasma lipids and lipoproteins, glycemic status, and other safety parameters were each analyzed with a longitudinal regression model using generalized estimating equations with random effects to take account of the within-person correlation between visits. The baseline value of the parameter, niacin treatment assignment, diabetes, obesity, follow-up visit number, and the interaction of diabetes, niacin assignment, and obesity were included as covariates. The initial screening value or, for lipoproteins, the mean of the first 2 screening values was used as the baseline value. Follow-up visit number was modeled both as a linear term and as an indicator variable to examine nonlinear effects. Models were reduced by backward elimination to the set of variables for which P<.05. Analyses were performed and verified using STATA statistical software (release 5.0, STATA Corp, College Station, Tex).
RESULTS
Patient Characteristics
Of the 468 ADMIT participants, 125 (27%) met study criteria for diabetes (Table 1 and Figure 1). ADMIT participants with diabetes were slightly older, had slightly higher body mass indices, higher HbA1c levels, and lower uric acid levels than those without diabetes. Participants with diabetes were more likely to be black and were less likely to be current cigarette smokers. Despite comparable ankle brachial index values, participants with diabetes were less likely to have had prior vascular procedures or symptoms of peripheral arterial disease. With the notable exception of HDL-C, which was lower among participants with diabetes, plasma lipids and lipoproteins at baseline were comparable in the 2 groups. When baseline characteristics were compared by niacin treatment assignment, participants with diabetes who were randomized to receive niacin placebo were older than those who received niacin (68 vs 66 years; P = .04). There were no other significant differences in baseline characteristics between niacin and niacin placebo groups in participants either with or without diabetes.
|
|
|
|
Table 1. Baseline Characteristics of ADMIT Participants With or Without Diabetes*
|
|
|
|
|
|
|
Figure 1. Flow Diagram of Study
Only the niacin arms of the ADMIT trial are shown.
|
|
|
Effect of Niacin on Plasma Lipid and Lipoprotein Levels
During the 12-week active niacin run-in period, a small decrease in total and LDL-C and triglycerides and increased HDL-C was detected in all participants as niacin was increased from 100 mg/d to 1000 mg/d (Figure 2). After randomization, participants both with and without diabetes who were receiving active niacin experienced a progressive further decrease in total and LDL-C as niacin dosage was increased to 3000 mg/d (Figure 2). Following randomization, HDL-C levels continued to increase and triglycerides decreased further in participants both with and without diabetes randomized to active niacin. Table 2 summarizes the baseline and treatment lipoprotein values by diabetes status and niacin treatment assignment. Niacin treatment resulted in significant decreases in LDL-C and triglycerides, and increased HDL-C compared with placebo control for participants both with and without diabetes. The reduction in total cholesterol, LDL-C, and triglycerides with niacin treatment were all significant (P<.001) in participants both with (-4%, -8%, -23%, respectively) and without diabetes (-7%, -9%, -28%, respectively). Levels of HDL-C were significantly increased by 29% and 29% in participants with and without diabetes, respectively (P<.001). Niacin therapy was equally effective in modifying lipoproteins in participants both with and without diabetes (interaction, P = .32-.66). The lipoprotein response to niacin was not affected by the presence of obesity (defined as body mass index >27 kg/m2 for men and >25 kg/m2 for women).
|
|
|
|
Figure 2. Effect of Niacin on Plasma Lipoproteins in Participants With and Without Diabetes
Data are expressed as mean plasma lipoprotein levels in mg/dL. During the 12-week active niacin run-in, all participants received niacin (maximal dose, 1000 mg/d). At week 0, participants were randomly assigned in double-blind fashion to receive niacin (closed circles, maximum dose, 3000 mg/d) or its placebo (open circles). Niacin treatment resulted in significant and equal reductions in plasma triglycerides, cholesterol, low-density lipoprotein cholesterol, and equivalent increase in high-density lipoprotein cholesterol in participants with and without diabetes (P<.001). To convert total, low-density lipoprotein, and high-density lipoprotein cholesterol from mg/dL to mmol/L, multiply by 0.0259. To convert triglycerides from mg/dL to mmol/L, multiply by 0.0113.
|
|
|
|
|
|
|
Table 2. Effect of Niacin on Lipid and Lipoprotein Levels From Baseline to Week 18 by Treatment Group for Participants With or Without Diabetes*
|
|
|
Effect of Niacin on Glycemic Status and Safety Parameters
Fasting glucose and HbA1c levels were monitored as indices of glycemic status during niacin treatment. Table 3 presents the glucose, HbA1c, and uric acid levels at baseline and the average of 6 postrandomization values. Niacin use resulted in a small but statistically significant increase in average glucose levels in participants both with (8.1 mg/dL [0.4 mmol/L]) and without diabetes (6.3 mg/dL [0.3 mmol/L]; P = .04 and P<.001, respectively). The effect of niacin on glucose was greater in participants with diabetes than without (P = .04). Figure 3 depicts the course of glucose values during the niacin treatment period. In subjects randomized to receive niacin, there was a transient increase in glucose as the niacin dosage was increased to 3000 mg/d; however, plasma glucose subsequently returned to baseline with continued niacin therapy (Figure 3). Niacin use also resulted in a small but statistically significant difference in change in HbA1c levels (0.3%) in participants with diabetes treated with niacin compared with those receiving niacin placebo (P = .04; Table 3). Niacin use had no effect on HbA1c levels in participants without diabetes (P = .38). The response of neither HbA1c nor glucose levels to niacin was significantly affected by obesity.
|
|
|
|
Table 3. Effect of Niacin on Average Plasma Glucose, Hemoglobin A1c, and Uric Acid in Participants With or Without Diabetes*
|
|
|
|
|
|
|
Figure 3. Effect of Niacin Treatment on Fasting Glucose in Participants With and Without Diabetes
All participants received niacin in doses up to 1000 mg/d during the initial 12-week active niacin run-in (baseline to week 0). At the end of the active niacin run-in period (week 0), participants were randomly assigned to receive continued niacin (titrated up to 3000 mg/d by week 18) or its placebo. Data are mg/dL of fasting glucose at baseline and subsequent follow-up visits by niacin treatment group. Niacin treatment was associated with a transient but statistically significant increase in glucose in participants with and without diabetes during follow-up (P = .05). The effect of niacin on plasma glucose was more pronounced in participants with vs without diabetes (P = .04). To convert fasting glucose from mg/dL to mmol/L, multiply by 0.0555.
|
|
|
Niacin increased uric acid levels over baseline values (P .001) similarly in both participants with and without diabetes (interaction, P = .19; Table 3). During follow-up, uric acid levels were higher than 595 µmol/L (range, 613-684 µmol/L) for 3 of 61 participants with diabetes assigned to niacin (5%) and for 1 of 59 participants with diabetes assigned to placebo (2%). The dose was lowered for 1 participant with diabetes assigned to niacin, but none had niacin discontinued. Among participants without diabetes, 4 had the niacin dosage reduced for uric acid levels exceeding the arbitrary limit of 595 µmol/L and niacin was discontinued in 1 participant. One participant with diabetes assigned to niacin and 1 without diabetes assigned to placebo had niacin discontinued due to possible gout.
Mean plasma alanine aminotransferase level was not significantly changed compared with baseline values (P = .09), nor was it higher in niacin-treated subjects compared with niacin-placebo treatment (P = .08). Further, plasma alanine aminotransferase was not higher with niacin treatment in participants with diabetes compared with those without (interaction, P = .38). The level of alanine aminotransferase was more than 3 times above the normal range (0-35 U/L) during follow-up for 2 participants with diabetes and 3 without, all of whom were taking niacin (P = .03) One participant without diabetes had niacin therapy discontinued because of an elevated alanine aminotransferase level.
The effect of niacin on plasma glucose and HbA1c levels could have been modified if hypoglycemic therapy was adjusted by primary caregivers in response to receiving reports of abnormal laboratory results. We therefore examined the frequency of insulin use and average dose of insulin used at baseline and at the final follow-up visit for participants with diabetes randomized to niacin vs those randomized to niacin placebo. Insulin use was increased by 13% in participants with diabetes randomized to niacin vs 4% in those randomized to niacin placebo (P = .09). For patients using insulin at both first and final follow-up visits (n = 26), there was no effect of niacin use on insulin dose (P = .68). There was also no significant change in use of oral hypoglycemic agents as a result of niacin use (P = .94).
Niacin use might also have resulted in development of diabetes in patients who did not have diabetes at entry into ADMIT. Therefore, we looked for new users of insulin or oral hypoglycemic agents among ADMIT participants who did not have diabetes at the baseline visit. Among the 173 participants randomized to niacin treatment who did not have diabetes at baseline, only 1 reported use of oral hypoglycemic therapy at subsequent follow-up visits. No niacin users without diabetes reported insulin use during follow-up, nor did any participants without diabetes who were randomized to niacin placebo report subsequent use of either insulin or oral hypoglycemic therapy.
Adherence to niacin therapy was comparable in ADMIT participants with and without diabetes, with niacin discontinuation rates of 23% and 16%, respectively (P = .20). Niacin discontinuation was also comparable in participants with diabetes randomized to receive active niacin and niacin placebo (23% vs 18%, respectively; P = .46). Glucose intolerance was listed as the reason for niacin discontinuation in 4 participants with diabetes (6%) who were randomized to active niacin and in 2 participants with diabetes (3%) randomized to niacin placebo (P = .44). Other reasons for discontinuation of niacin in participants with diabetes included comorbid vascular disease, patient request, and acanthosis nigricans. The protocol specified down-titration of niacin if HbA1c level exceeded 10%. This HbA1c limit was exceeded after randomization in 18 participants with diabetes, 10 of whom were assigned to niacin and 8 assigned to placebo. The average dose of niacin at week 18 was 2553 mg in participants with diabetes, and was 2626 mg in participants without diabetes (P = .44).
COMMENT
Lipid-modifying therapy is recommended in both peripheral arterial disease and diabetes to reduce the risk of atherosclerotic vascular disease.13, 16 Although current guidelines focus on LDL-C as a risk factor, hypertriglyceridemia and low HDL-C are common in the dyslipidemia associated with type 2 diabetes mellitus,10-11,13 and contribute to the increased risk of arterial vascular disease in subjects with diabetes. Despite its proven ability to increase HDL and lower triglycerides, the use of niacin has been discouraged in patients with diabetes,10-13 largely due to reports of deterioration of glycemic control in subjects both with and without diabetes who were treated with niacin.3, 17-19 The effect of niacin on glycemic status in patients with diabetes has, however, not previously been assessed in the setting of a randomized, placebo-controlled trial. We therefore decided to assess the safety and efficacy of niacin use in ADMIT participants with diabetes.
This report demonstrates that immediate-release niacin is equally effective in modifying lipid and lipoprotein levels in subjects with and without diabetes. We also confirmed previous observations of increased plasma glucose levels in patients both with and without diabetes and treated with lipid-modifying doses of niacin; however, the effects observed over 60 weeks of follow-up were relatively modest and did not result in significantly increased rates of niacin discontinuation or alterations in hypoglycemic therapy. It is important to note, however, that the results observed here might not reflect those obtained with other niacin formulations, and that glycemic therapy may have been modified in individual patients as a result of niacin treatment.
Previous reports of niacin-induced glucose intolerance are derived largely from uncontrolled case reports involving small numbers of subjects.17-20 Many of these earlier studies were performed on subjects without diabetes.18-20 Of studies conducted on subjects with diabetes, some,3, 17 but not all,21-22 reported worsened glycemic control with niacin treatment. In addition, in these studies, glucose tolerance was examined within 2 to 8 weeks following rapid institution of lipid-lowering doses of niacin (3-6 g/d).3, 18-20 The glucose intolerance following niacin therapy in these reports may reflect short-term effects from rapid institution of lipid-lowering doses of niacin. In the present study we, in fact, observed a transient increase in plasma glucose as niacin was titrated to its maximum dose.
The only other report that includes a number of subjects comparable with our own is a retrospective study of niacin use at a Department of Veterans Affairs Medical Center.23 This study reported higher niacin discontinuation rates overall and higher rates of discontinuation due to poor glycemic status in patients with diabetes treated with a slow-release niacin preparation. In that study, niacin was administered without blinding or use of placebo controls. Given the current perception that niacin significantly worsens glycemic status, it is possible that physician bias may have influenced the niacin discontinuation rate. These findings may also reflect a difference between sustained release and crystalline (immediate release) niacin and/or the reliance on blood glucose rather than HbA1c level for clinical decision making.
Although the effect of niacin treatment on glycemic status overall was modest in ADMIT, our findings do not preclude the possibility that its use, particularly at doses higher than those used here, or using preparations other than crystalline niacin, may significantly adversely affect glycemic control in individual patients with diabetes. Therefore, glycemic status should be carefully monitored during niacin therapy in patients with diabetes, and the dose modified or discontinued if glycemic status clearly deteriorates. In addition, plasma insulin was not measured nor was insulin resistance formally assessed in this study. Several studies have shown decreased glucose tolerance and increased plasma insulin levels in subjects without diabetes following short-term niacin treatment.18-19,22, 24 A more recent study,25 however, has shown minimal effect of short-term niacin treatment on insulin levels and glucose use in normal volunteers. It is also possible that the changes in glycemic indices observed here, although relatively modest, might offset some of the cardiovascular risk reduction with niacin.
Recently published guidelines for treatment of dyslipidemia in type 2 diabetes mellitus recommend aggressive lipid modification using statin drugs or fibrates.12 Although LDL-C is recommended as the primary target of therapy, it is recognized that hypertriglyceridemia and decreased HDL-C are highly prevalent in type 2 diabetes mellitus, and are associated with increased risk of atherosclerotic vascular disease.10, 13 Niacin effectively reduces plasma triglycerides by reducing hepatic production of very LDL, and increases HDL cholesterol by up to 30%, possibly by reducing hepatic removal of apolipoprotein A-1.26-27 Niacin also reduces plasma LDL-C by 10% to 15% and normalizes LDL particle size distribution.28 Although the LDL-C lowering effect of niacin is modest compared with that of statin drugs, niacin has a greater effect on HDL-C, triglycerides, and lipoprotein (a).4 For patients with diabetes who have hypertriglyceridemia or low HDL-C or both, gemfibrozil has been shown to be effective and does not adversely affect glycemic status29; however, not all patients tolerate gemfibrozil therapy. Furthermore, in cases of extreme hypertriglyceridemia, combination therapy with gemfibrozil and niacin may be required to reduce triglycerides to acceptable levels.
There is limited information about which of the currently available lipid-modifying interventions offer the greatest benefit for patients with diabetes in terms of reduced cardiovascular morbidity and mortality. A recent post-hoc analysis of the Scandinavian Simvastatin Survival Study (4-S) indicates that participants with diabetes experienced a significant reduction in coronary heart disease events with simvastatin therapy.30 In the Helsinki Heart study, patients with diabetes experienced a 60% reduction in coronary heart disease events with gemfibrozil therapy.31 This decrease was not statistically significant, however, because of the small number of participants with diabetes in that study. Similarly, in the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), participants with diabetes experienced coronary heart disease event reduction with gemfibrozil equivalent to that observed in the entire cohort.32 Although the effect of niacin on cardiovascular morbidity and mortality has not been demonstrated specifically in diabetes, niacin therapy has been shown to reduce vascular disease morbidity and mortality in general populations of subjects with atherosclerotic vascular disease.5-8
Despite current recommendations against use of niacin in diabetes,10, 12 the present study demonstrates that lipid-modifying doses of immediate-release niacin can be used safely in patients with stable, controlled, type 2 diabetes mellitus. Niacin therapy may be considered as an alternative to statin drugs or fibrates in patients with diabetes in whom these agents are not tolerated, or in whom they fail to sufficiently correct hypertriglyceridemia or low HDL-C. Conversely, in view of the absence of an effect on glycemic status of statin drugs or fibrates, these agents should still be considered first-line therapy in diabetic dyslipidemia.
AUTHOR INFORMATION
Financial Disclosure: Dr Hunninghake received research funding from Upsher-Smith Laboratories for niacor. Drs Elam, Hunninghake, Kostis, and Brinton received research funding from Bristol-Myers Squibb Co for pravastatin. Drs Elam, Kostis, Sheps, and Brinton are part of the Speakers Bureau for Bristol-Myers Squibb Co. Dr Kostis is a consultant for Bristol-Myers Squibb Co.
Funding/Support: The Arterial Disease Multiple Intervention Trial is funded by the National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications (contract HC-25110-6) and the Statistics and Epidemiology Research Corp (contract NOI-HC-35124); and by grant MO1-RROO21 from the Clinical Research Centers at the University of Tennessee, Memphis, grant MOI-RR-0400 from the University of Minnesota, Minneapolis, grant MO1-RR-00350 from Baylor University, Houston, Tex, grant 5-MOI-RR-00046 from the University of North Carolina, Chapel Hill, and grant MO1-RR07122 from the Bowman-Gray School of Medicine, Wake Forest University, Winston-Salem, NC. Study medication was donated by Upsher-Smith Laboratories and Bristol-Myers Squibb Co.
The ADMIT Study Group: Clinical Centers: Bowman-Gray School of Medicine, Wake Forest University, Winston-Salem, NC: John R. Crouse, MD, Eliot A. Brinton, MD, Gregory Burke, MD, Grethe Tell, PhD, Estelle King, PA-C, and Donna Davis, LPN; Baylor College of Medicine/Texas Heart Institute, Houston, Tex: J. Alan Herd, MD, Susan McRee, RN, Sydney Colvill, RN, Peter H. Jones, MD, Henry Pownall, PhD, William K. Vaugh, PhD, James J. Ferguson, MD, and Mary Harlan, RN; University of Minnesota, Minneapolis: Donald B. Hunninghake, MD, Jennifer Robinson, MD, Timothy J. Wilt, MD, MPH, Alan Hirsch, MD, Janet Bricher, RN, and Scott Rajala; University of North Carolina, Chapel Hill: David Sheps, MD, Ross Simpson, MD, MPH, Celeste Lindley, PharmD, Rungraj Kittayaphong, MD, Tracey Eatmon, PharmD, Pamela Haines, DRPH, RD, Hennan A. Tyroler, MD, and Eileen Dittman, RN; Robert Wood Johnson School of Medicine, Robert Wood Johnson University, New Brunswick, NJ: John B. Kostis, MD, Daniel M. Shindler, MD, Donna Hoagland, LPN, Celeste Cardona, LPN, and Amy Finn O'Connor, LPN; University of Tennessee, Memphis: Marshall B. Elam, PhD, MD, Kathleen Nash, MSN, Lisa Jones, RN, Lynne Lichtermann, BSN, Beate Griffin, RN, Michael York, Lisa Anderson, Jan Elam, BS, Evelyn Clark, Alice Wallace, RN, and William B. Applegate, MD, MPH; Drug Distribution Center: US Public Health Service, Supply Service Center, Perry Point, Md: Lorraine D'Angelo, Thomas Shaffer, Kathleen Scott, and Chris Konrad; Coordinating Center: Axio Research Corp, Seattle Wash: Kathryn B. Davis, PhD, J. Ward Kennedy, MD, Mary B. Pettinger, MS, Daniel Brown, BS, W. Craig Johnson, MS, and Laura DeVoe, LPN; Project Office: Clinical Trial Scientific Research Group, Bethesda, Md: Rekha Garg, MD, MS, Debra Egan, MSc, MPH, Jeff Probstfield, MD, Myron Waclawiw, PhD, John Taylor; Lipid Analytic Laboratory: Bowman-Gray School of Medicine, Wake Forest University, Winston-Salem, NC: Richard W. St. Clair, PhD.
Corresponding Author and Reprints: Marshall B. Elam, PhD, MD, Division of Clinical Pharmacology, University of Tennessee, 874 Union Ave, Memphis, TN 38163.
Author Affiliations: University of Tennessee Health Science Center (Dr Elam), Memphis Veterans Affairs Medical Center (Dr Elam), Memphis, Tenn; University of Minnesota, Minneapolis (Dr Hunninghake); University of Washington (Dr Davis), Axio Research Corp (Dr Davis and Mr Johnson), Seattle, Wash; Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md (Dr Garg and Ms Egan); Robert Wood Johnson School of Medicine, Robert Wood Johnson University, New Brunswick, NJ (Dr Kostis); University of North Carolina, Chapel Hill (Dr Sheps); and Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC (Dr Brinton).
Dr Garg is now with Eli Lilly Co; Dr Sheps is now with the University of Florida College of Medicine, Gainesville; and Dr Brinton is now with the University of Arizona College of Medicine, Tucson.
REFERENCES
| |
1. Altschul R, Hoffer A, Stephen J. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558-559.
FULL TEXT
2. Knopp R, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-650.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
3. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723-726.
FREE FULL TEXT
4. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med. 1994;154:1586-1595.
FREE FULL TEXT
5. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
FREE FULL TEXT
6. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
ABSTRACT
7. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
ABSTRACT
8. Blankenhorn D, Nessim S, Johnson R, Sanmarco M, Azen S, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
FREE FULL TEXT
9. Gordon T, Kannel W. Predisposition to atherosclerosis of the head, heart and legs: the Framingham Study. JAMA. 1972;221:661-666.
FREE FULL TEXT
10. Garg A. Lipid-lowering therapy and macrovascular disease in diabetes mellitus. Diabetes. 1992;41:111-115.
11. Oki JC. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy. Pharmacotherapy. 1995;15:317-337.
WEB OF SCIENCE
| PUBMED
12. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:179-182.
WEB OF SCIENCE
| PUBMED
13. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21:160-178.
ABSTRACT
14. Egan DA, Garg R, Wilt TJ, et al for the ADMIT Investigators. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol. 1999;83:569-575.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
15. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
ABSTRACT
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
FREE FULL TEXT
17. Molnar G, Berge K, Rosevear J, McGuckin W, Achor R. The effect of nicotinic acid in diabetes mellitus. Metabolism. 1964;13:181-190.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
18. Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid–induced insulin resistance. Diabetes. 1989;38:562-568.
ABSTRACT
19. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism. 1971;20:1031-1035.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
20. Miettinen T, Taskinen M-R, Nikkila E. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand. 1969;186:247-253.
WEB OF SCIENCE
| PUBMED
21. Parsons W. Studies of nicotinic acid use in hypercholesterolemia. Arch Intern Med. 1961;107:85-99.
22. Gurian H, Adlersberg D. The effect of large doses of nicotinic acid on circulation, lipids and carbohydrate tolerance. Am J Med Sci. 1959;237:12-22.
WEB OF SCIENCE
| PUBMED
23. Gray D, Morgan T, Chretien S, Kashyap M. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121:252-258.
FREE FULL TEXT
24. Tornvall P, Walldius G. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia: effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J Intern Med. 1991;230:415-421.
WEB OF SCIENCE
| PUBMED
25. Alvarsson M, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest. 1996;56:563-570.
WEB OF SCIENCE
| PUBMED
26. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981;22:24-36.
ABSTRACT
27. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 1997;17:2020-2028.
FREE FULL TEXT
28. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
FREE FULL TEXT
29. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM Diabetes. 1989;38:364-372. [published erratum appears in Diabetes. 1990;39:1313].
30. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
ABSTRACT
31. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-825.
ABSTRACT
32. Rubins HB, Robins SJ, Collins D, et al for the VA-HIT Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
September 13, 2000
JAMA. 2000;284(10):1317-1318.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes
Faul et al.
Clin Med Res 2009;7:14-20.
ABSTRACT
| FULL TEXT
Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins?
Goumas
ANGIOLOGY 2009;60:93-98.
ABSTRACT
Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT
Investigation and management of hypertriglyceridaemia
Ferns et al.
J. Clin. Pathol. 2008;61:1174-1183.
ABSTRACT
| FULL TEXT
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Postgrad. Med. J. 2008;84:590-598.
ABSTRACT
| FULL TEXT
Peripheral Arterial Disease: Diagnosis and Management
Arain and Cooper
Mayo Clin Proc. 2008;83:944-950.
ABSTRACT
| FULL TEXT
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy and Yellon
Heart 2008;94:706-714.
ABSTRACT
| FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
J Am Coll Cardiol 2008;51:1512-1524.
FULL TEXT
Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
Diabetes Care 2008;31:811-822.
FULL TEXT
Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Goldberg and Jacobson
Mayo Clin Proc. 2008;83:470-478.
ABSTRACT
| FULL TEXT
HDL-cholesterol modulation and its impact on the management of cardiovascular risk
Ferns and Keti
Ann Clin Biochem 2008;45:122-128.
ABSTRACT
| FULL TEXT
Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT
Hypertriglyceridemia
Brunzell
NEJM 2007;357:1009-1017.
FULL TEXT
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT
| FULL TEXT
The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Windler et al.
Diabetes and Vascular Disease Research 2007;4:136-142.
ABSTRACT
Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner
British Journal of Diabetes & Vascular Disease 2007;7:25-30.
ABSTRACT
Standards of Medical Care in Diabetes--2007
American Diabetes Association
Diabetes Care 2007;30:S4-S41.
FULL TEXT
Diabetic dyslipidaemia: the triad
Wierzbicki
Eur Heart J Suppl 2006;8:F30-F33.
ABSTRACT
| FULL TEXT
Time-Dependent Effects of Free Fatty Acids on Glucose Effectiveness in Type 2 Diabetes
Kishore et al.
Diabetes 2006;55:1761-1768.
ABSTRACT
| FULL TEXT
Hypertriglyceridemia.
Pejic and Lee
J Am Board Fam Med 2006;19:310-316.
ABSTRACT
| FULL TEXT
Management of Dyslipidemia in Special Populations
Tovar and Schering
Journal of Pharmacy Practice 2006;19:63-78.
ABSTRACT
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg
J. Clin. Endocrinol. Metab. 2006;91:383-392.
ABSTRACT
| FULL TEXT
Low HDL cholesterol levels.
Itskowitz et al.
NEJM 2006;354:417-419.
FULL TEXT
Standards of Medical Care in Diabetes-2006
American Diabetes Association
Diabetes Care 2006;29:S4-S42.
FULL TEXT
Managing Abnormal Blood Lipids: A Collaborative Approach
Fletcher et al.
Circulation 2005;112:3184-3209.
ABSTRACT
| FULL TEXT
Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
Van Gaal et al.
British Journal of Diabetes & Vascular Disease 2005;5:344-350.
ABSTRACT
2nd International Symposium on Triglycerides and HDL: Lipid abnormalities and their treatment
Diabetes Care 2005;28:2795-2802.
FULL TEXT
The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor
Espinosa-Larranaga et al.
Diabetes and Vascular Disease Research 2005;2:S1-S8.
ABSTRACT
Inflammation, Atherosclerosis, and Aspects of Insulin Action
Bloomgarden
Diabetes Care 2005;28:2312-2319.
FULL TEXT
Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey
Youssef et al.
ANGIOLOGY 2005;56:279-287.
ABSTRACT
Dyslipidaemia among Indo-Asians strategies for identification and management
Enas et al.
British Journal of Diabetes & Vascular Disease 2005;5:81-90.
ABSTRACT
Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C
Barter
British Journal of Diabetes & Vascular Disease 2005;5:S1-S15.
ABSTRACT
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT
| FULL TEXT
Standards of Medical Care in Diabetes
American Diabetes Association
Diabetes Care 2005;28:S4-S36.
FULL TEXT
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT
Prevention and Treatment of the Metabolic Syndrome
Daskalopoulou et al.
ANGIOLOGY 2004;55:589-612.
ABSTRACT
Abdominal Obesity and Dyslipidemia in the Metabolic Syndrome: Importance of Type 2 Diabetes and Familial Combined Hyperlipidemia in Coronary Artery Disease Risk
Carr and Brunzell
J. Clin. Endocrinol. Metab. 2004;89:2601-2607.
ABSTRACT
| FULL TEXT
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT
| FULL TEXT
Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome
Mcgovern
British Journal of Diabetes & Vascular Disease 2004;4:78-85.
ABSTRACT
The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin
Ito
The Annals of Pharmacotherapy 2004;38:277-285.
ABSTRACT
| FULL TEXT
Standards of Medical Care in Diabetes
Diabetes Care 2004;27:s15-35.
FULL TEXT
Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia
Meyers et al.
ANN INTERN MED 2003;139:996-1002.
ABSTRACT
| FULL TEXT
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part II
Luscher et al.
Circulation 2003;108:1655-1661.
FULL TEXT
Medical Management of Hyperlipidemia/Dyslipidemia
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2003;88:2445-2461.
FULL TEXT
Niacin as a Component of Combination Therapy for Dyslipidemia
Miller
Mayo Clin Proc. 2003;78:735-742.
ABSTRACT
Change in {alpha}1 HDL Concentration Predicts Progression in Coronary Artery Stenosis
Asztalos et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:847-852.
ABSTRACT
| FULL TEXT
The Use of Niacin in Diabetes Mellitus
Mikhail
Arch Intern Med 2003;163:369-369.
FULL TEXT
Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines
Mooradian
Arch Intern Med 2003;163:33-40.
ABSTRACT
| FULL TEXT
Standards of Medical Care for Patients With Diabetes Mellitus
Diabetes Care 2003;26:S33-S50.
FULL TEXT
References
Circulation 2002;106:3373-3421.
FULL TEXT
Common Drug Pathways and Interactions
Kroner
Diabetes Spectr. 2002;15:249-255.
ABSTRACT
| FULL TEXT
Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
Grundy et al.
Arch Intern Med 2002;162:1568-1576.
ABSTRACT
| FULL TEXT
New Strategies for the Treatment of Diabetic Dyslipidemia
Haffner and Goldberg
Diabetes Care 2002;25:1237-1239.
FULL TEXT
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman et al.
JAMA 2002;287:2570-2581.
ABSTRACT
| FULL TEXT
Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity
Hiatt
Eur Heart J Suppl 2002;4:B50-B54.
ABSTRACT
Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications
Franz et al.
Diabetes Care 2002;25:148-198.
FULL TEXT
Lp A-I and Niacin: New Views of an Antiatherogenic Duo
Saucan and Brinton
Arterioscler. Thromb. Vasc. Bio. 2001;21:1707-1709.
FULL TEXT
The American Diabetes Association's 48th Annual Advanced Postgraduate Course
Bloomgarden
Diabetes Care 2001;24:1489-1495.
FULL TEXT
Medical Treatment of Peripheral Arterial Disease and Claudication
Hiatt
NEJM 2001;344:1608-1621.
FULL TEXT
Niacin Safe and Effective Lipid Therapy for Diabetics
JWatch General 2000;2000:4-4.
FULL TEXT
|
